Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib with Irinotecan and Temozolomide for Refractory or Recurrent Neuroblastoma
NCT04842526Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of anlotinib in neuroblastoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04842526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842526.